Soluble adenylyl cyclases and lung endothelium health after infection
Official title: Soluble adenylyl cyclases in lung endothelial tauopathy
Funded at University of South Alabama · NIH-11307055 · Data updated 2026-11-12
A patient-friendly look at a research effort to understand how a common lung infection can damage the blood vessels in the lungs and how this damage could be reduced.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of South Alabama NIH-funded |
| Lab location | 1 site (Mobile, United States) |
| Project start | March 20, 2023 |
| Project end | February 28, 2027 |
| Funding year | 2026 |
| Award (this year) | $471,393 |
| NIH project number | 5R01HL167997-04 |
| Project ID | NIH-11307055 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with acute lung injury or pneumonia-related lung barrier damage could benefit from advances guided by this research.
✕Less likely to help
There is no direct patient intervention in this basic science project, so immediate personal medical benefit is not guaranteed.
What this research studies
This project explores how a lung infection with Pseudomonas aeruginosa damages the tiny blood vessels in the lungs by altering chemical signals inside endothelial cells. Researchers study enzymes that make cyclic nucleotides and how these signals lead to tau protein changes, microtubule breakdown, and reduced ability to repair the lung barrier after infection. By uncovering these pathways, the work aims to point toward new ways to protect the lung lining and support recovery after infection. The study uses lab experiments with human-relevant cell systems and analyzes how changes in signaling might be stopped or reversed.
Why it matters
Potential benefit: If successful, the findings could inform new strategies to preserve lung barrier function and speed recovery from severe lung infections.
How similar studies have gone: Prior research has linked cyclic nucleotide signaling and endothelial damage to lung injury, suggesting this pathway is a promising target but specific mechanisms are still being clarified.
Where this research is happening
-
University of South Alabama
Mobile, United States Active
Researchers
- Principal investigator: Stevens, Troy — University of South Alabama
- Study coordinator: Stevens, Troy
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.